KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash from Financing Activities (2018 - 2025)

Moderna (MRNA) has disclosed Cash from Financing Activities for 8 consecutive years, with $581.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 19466.67% to $581.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $593.0 million, a 958.93% increase, with the full-year FY2025 number at $593.0 million, up 958.93% from a year prior.
  • Cash from Financing Activities was $581.0 million for Q4 2025 at Moderna, up from -$1.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $581.0 million in Q4 2025 to a low of -$1.3 billion in Q2 2022.
  • A 5-year average of -$252.4 million and a median of -$13.5 million in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: crashed 51950.0% in 2022, then soared 19466.67% in 2025.
  • Moderna's Cash from Financing Activities stood at -$873.0 million in 2021, then soared by 49.83% to -$438.0 million in 2022, then skyrocketed by 75.11% to -$109.0 million in 2023, then surged by 97.25% to -$3.0 million in 2024, then skyrocketed by 19466.67% to $581.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Cash from Financing Activities are $581.0 million (Q4 2025), -$1.0 million (Q3 2025), and $9.0 million (Q2 2025).